<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01557452</url>
  </required_header>
  <id_info>
    <org_study_id>DSC/11/2357/42</org_study_id>
    <secondary_id>2011-003341-18</secondary_id>
    <nct_id>NCT01557452</nct_id>
  </id_info>
  <brief_title>Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis</brief_title>
  <official_title>An Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Polyarticular Course Juvenile Idiopathic Arthritis (Poly JIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italfarmaco</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Italfarmaco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective of the study:&#xD;
&#xD;
      the purpose of this extension study was to determine the safety of Givinostat in a long term&#xD;
      treatment of patients who participated in DSC/08/2357/36 study with good results (clinical&#xD;
      benefit at least pediACR30 response);&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Givinostat is expected to exert a clinically relevant therapeutic effect on polyarticular JIA&#xD;
      through the inhibition of the production/release of pro-inflammatory cytokines, such as&#xD;
      IL-1β, IL-6 and TNFα, which are involved in the pathogenesis of the arthritic process.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Previous study DSC/08/2357/36 did not show efficacy for Givinostat in JIA. Sponsor decision to&#xD;
    stop development of Givinostat in polyarticular course Juvenile Idiopathic Arthritis wasn't&#xD;
    related to any tolerability concerns.&#xD;
  </why_stopped>
  <start_date type="Actual">December 28, 2011</start_date>
  <completion_date type="Actual">January 27, 2014</completion_date>
  <primary_completion_date type="Actual">January 27, 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAE) and Adverse Events (AE) of Interest</measure>
    <time_frame>Through end of treatment, up to 108 weeks.</time_frame>
    <description>During the entire study period it was reported only one adverse event considered not drug related by the investigator (Mild flu at week 107 of study treatment).&#xD;
No action was taken and the patient recovered spontaneously</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Maintained PedACR30 Response</measure>
    <time_frame>At weeks 48, 60 and 108</time_frame>
    <description>This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30).&#xD;
PedACR30 is defined as at least a 30% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%:&#xD;
physician's global assessment of disease activity;&#xD;
parent/guardian's or patient's global assessment of overall wellbeing;&#xD;
functional ability;&#xD;
number of joints with active arthritis;&#xD;
number of joints with limited range of motion;&#xD;
ESR.&#xD;
(ACR stands for American College of Rheumatology)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Reached PedACR70 Response</measure>
    <time_frame>At weeks 48, 60 and 108</time_frame>
    <description>This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30).&#xD;
PedACR70 is defined as at least a 70% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%:&#xD;
physician's global assessment of disease activity;&#xD;
parent/guardian's or patient's global assessment of overall wellbeing;&#xD;
functional ability;&#xD;
number of joints with active arthritis;&#xD;
number of joints with limited range of motion;&#xD;
ESR.&#xD;
(ACR stands for American College of Rheumatology)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Givinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient received the dose of 0.75 mg/kg BID from December 28th, 2011 to January 27th, 2014</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Givinostat</intervention_name>
    <description>ready-to-use oral suspension, administered in fed condition and on a outpatient basis, especially intended for paediatric patients</description>
    <arm_group_label>Givinostat</arm_group_label>
    <other_name>ITF2357</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects who had successfully completed the previous Dose Finding Study and were fully&#xD;
             compliant to the inclusion/exclusion criteria described in the previous DSC/08/2357/36&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with fever related to JIA or other systemic features of JIA during 12 months&#xD;
             before entering the study&#xD;
&#xD;
          -  active bacterial or mycotic infection requiring antimicrobial treatment&#xD;
&#xD;
          -  episode of macrophage activation syndrome over the last 6 months&#xD;
&#xD;
          -  baseline prolongation of QT/QTc interval, use of concomitant medications that prolong&#xD;
             the QT/QTc interval or history of additional risk factors for TdP.&#xD;
&#xD;
          -  clinically significant cardiovascular disease&#xD;
&#xD;
          -  clinically significant illness i.e. any condition that in the opinion of the&#xD;
             Investigator places the patient to unacceptable risk for adverse outcome if he/she&#xD;
             were to participate in the study&#xD;
&#xD;
          -  psychiatric illness/social situation that would limit compliance with study medication&#xD;
             and protocol requirements&#xD;
&#xD;
          -  inherited metabolic diseases&#xD;
&#xD;
          -  presence of malignancy&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  positive blood test for HIV&#xD;
&#xD;
          -  active EBV infection, active B and/or C hepatitis&#xD;
&#xD;
          -  platelet count &lt;100x10(9)/L&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavla Dolezalova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Faculty Hospital Department of Pediatrics and Adolescent Medicine, Praha, Czech Republic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1st Faculty of Medicine and General Faculty Hospital</name>
      <address>
        <city>Praha</city>
        <zip>12109</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 14, 2012</study_first_submitted>
  <study_first_submitted_qc>March 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2012</study_first_posted>
  <results_first_submitted>February 8, 2021</results_first_submitted>
  <results_first_submitted_qc>March 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 6, 2021</results_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JIA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Givinostat hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Givinostat</title>
          <description>Givinostat: oral suspension, 0,75 mg/Kg b.i.d. in fed conditions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Givinostat</title>
          <description>Givinostat: oral suspension, 0,75 mg/Kg b.i.d. in fed conditions</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events (SAE) and Adverse Events (AE) of Interest</title>
        <description>During the entire study period it was reported only one adverse event considered not drug related by the investigator (Mild flu at week 107 of study treatment).&#xD;
No action was taken and the patient recovered spontaneously</description>
        <time_frame>Through end of treatment, up to 108 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Givinostat</title>
            <description>Givinostat: oral suspension, 0,75 mg/Kg b.i.d. in fed conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAE) and Adverse Events (AE) of Interest</title>
          <description>During the entire study period it was reported only one adverse event considered not drug related by the investigator (Mild flu at week 107 of study treatment).&#xD;
No action was taken and the patient recovered spontaneously</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>non serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Maintained PedACR30 Response</title>
        <description>This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30).&#xD;
PedACR30 is defined as at least a 30% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%:&#xD;
physician's global assessment of disease activity;&#xD;
parent/guardian's or patient's global assessment of overall wellbeing;&#xD;
functional ability;&#xD;
number of joints with active arthritis;&#xD;
number of joints with limited range of motion;&#xD;
ESR.&#xD;
(ACR stands for American College of Rheumatology)</description>
        <time_frame>At weeks 48, 60 and 108</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Givinostat</title>
            <description>Givinostat: oral suspension, 0,75 mg/kg b.i.d. in fed conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Maintained PedACR30 Response</title>
          <description>This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30).&#xD;
PedACR30 is defined as at least a 30% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%:&#xD;
physician's global assessment of disease activity;&#xD;
parent/guardian's or patient's global assessment of overall wellbeing;&#xD;
functional ability;&#xD;
number of joints with active arthritis;&#xD;
number of joints with limited range of motion;&#xD;
ESR.&#xD;
(ACR stands for American College of Rheumatology)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Reached PedACR70 Response</title>
        <description>This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30).&#xD;
PedACR70 is defined as at least a 70% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%:&#xD;
physician's global assessment of disease activity;&#xD;
parent/guardian's or patient's global assessment of overall wellbeing;&#xD;
functional ability;&#xD;
number of joints with active arthritis;&#xD;
number of joints with limited range of motion;&#xD;
ESR.&#xD;
(ACR stands for American College of Rheumatology)</description>
        <time_frame>At weeks 48, 60 and 108</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Givinostat</title>
            <description>Givinostat: oral suspension, 0,75 mg/kg b.i.d. in fed conditions</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Reached PedACR70 Response</title>
          <description>This is an open-label treatment extension of the 2010-019094-15 study, an antecedent dose-ranging trial of Givinostat ready-to-use oral suspension formulation. Eligible patients were those who had completed the previous study achieving a clinical benefit, i.e. patients achieving at least an ACR Paediatric 30 (PedACR30).&#xD;
PedACR70 is defined as at least a 70% improvement from baseline in any three of the following six variables in juvenile idiopathic arthritis (JIA) patients, with no more than one variable worsening by more than 30%:&#xD;
physician's global assessment of disease activity;&#xD;
parent/guardian's or patient's global assessment of overall wellbeing;&#xD;
functional ability;&#xD;
number of joints with active arthritis;&#xD;
number of joints with limited range of motion;&#xD;
ESR.&#xD;
(ACR stands for American College of Rheumatology)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 108</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through end of treatment, up to 108 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Givinostat</title>
          <description>Givinostat: oral suspension, 0,75 mg/kg b.i.d. in fed conditions</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paolo Bettica, MD</name_or_title>
      <organization>Italfarmaco SpA</organization>
      <phone>+39 02 64431</phone>
      <email>p.bettica@italfarmaco.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

